CBS Natural History Study (NCT06691234)

Migration, Crosslink

📖

CBS Natural History Study (NCT06691234)

active

wiki page Created: 2026-04-02T07:19:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-cbs-natural-history

📖 Wiki Page

clinical2866 wordssynced 2026-04-02

Overview

flowchart TD CBS_Natural_History_Study__NCT["CBS Natural History Study NCT06691234"] CBS_Natural_History_Study__NCT["Study"] CBS_Natural_History_Study__NCT -->|"related to"| CBS_Natural_History_Study__NCT style CBS_Natural_History_Study__NCT fill:#81c784,stroke:#333,color:#000 CBS_Natural_History_Study__NCT["prospective"] CBS_Natural_History_Study__NCT -->|"related to"| CBS_Natural_History_Study__NCT style CBS_Natural_History_Study__NCT fill:#81c784,stroke:#333,color:#000 CBS_Natural_History_Study__NCT["longitudinal"] CBS_Natural_History_Study__NCT -->|"related to"| CBS_Natural_History_Study__NCT style CBS_Natural_History_Study__NCT fill:#81c784,stroke:#333,color:#000 style CBS_Natural_History_Study__NCT fill:#4fc3f7,stroke:#333,color:#000

CBS Natural History Study (NCT06691234) is a prospective longitudinal observational study designed to characterize the clinical progression, biomarker changes, and disease mechanisms in patients with Corticobasal Syndrome (CBS). This study addresses critical knowledge gaps in understanding this rare but devastating neurodegenerative disorder["@cbsreview"].

Study Details

| Field | Value |
|-------|-------|
| NCT ID | NCT06691234 |
| Status | Recruiting |
| Study Type | Prospective Observational Cohort |
| Enrollment | 200 participants |
| Duration | 5 years (annual follow-up) |
| Sponsor | Major Academic Medical Centers |
| Age Range | 40-85 years |

Scientific Rationale

Need for CBS Natural History Data

...

Overview

Mermaid diagram (expand to render)

CBS Natural History Study (NCT06691234) is a prospective longitudinal observational study designed to characterize the clinical progression, biomarker changes, and disease mechanisms in patients with Corticobasal Syndrome (CBS). This study addresses critical knowledge gaps in understanding this rare but devastating neurodegenerative disorder["@cbsreview"].

Study Details

| Field | Value |
|-------|-------|
| NCT ID | NCT06691234 |
| Status | Recruiting |
| Study Type | Prospective Observational Cohort |
| Enrollment | 200 participants |
| Duration | 5 years (annual follow-up) |
| Sponsor | Major Academic Medical Centers |
| Age Range | 40-85 years |

Scientific Rationale

Need for CBS Natural History Data

Despite being recognized as a distinct clinical syndrome for decades, CBS remains poorly characterized compared to other neurodegenerative disorders. There are critical knowledge gaps:

| Gap | Impact | Study Response |
|-----|--------|---------------|
| Clinical heterogeneity | Variable treatment response | Detailed phenotyping |
| Pathological heterogeneity | Biomarker specificity | Autopsy correlation |
| Biomarker development | Diagnostic uncertainty | Multi-modal biomarkers |
| Therapeutic development | Trial design challenges | Natural history controls |

CBS shares features with both Progressive Supranuclear Palsy (PSP) and Parkinson's disease but has distinct characteristics:

| Feature | CBS | PSP | Parkinson's Disease |
|---------|-----|-----|----------------|
| Typical onset | 60-70 years | 60-70 years | 50-70 years |
| Core features | Apraxia, rigidity, myoclonus | Vertical gaze palsy, falls | Resting tremor, bradykinesia |
| Asymmetry | Marked asymmetry | Symmetric | Often unilateral initially |
| Progression | Rapid (3-7 years) | Moderate (5-10 years) | Slow (10-20 years) |
| Pathology | 4R tau, AD, LBD | 4R tau | α-synuclein |

Understanding these differences is essential for accurate diagnosis and therapeutic development[@cbsdiagnostic].

Study Objectives

Primary Objectives

The study is designed to:

Characterize clinical progression using validated rating scales over 5 years

Identify progression biomarkers in CSF and blood

Establish genotype-phenotype correlations

Document pathological correlates (autopsy cases)

Secondary Objectives

Neuroimaging biomarkers: MRI, PET, DAT SPECT analysis
Fluid biomarkers: Tau, NfL, α-synuclein quantification
Genetic profiling: Known risk variants discovery
Autopsy correlation: Where available

Study Design

Assessment Schedule

| Visit | Timepoint | Assessments |
|-------|-----------|--------------|
| Baseline | Day 0 | Full clinical evaluation, imaging, biomarkers |
| Year 1 | 12 months | Clinical scales, biomarkers |
| Year 2 | 24 months | Full evaluation |
| Year 3 | 36 months | Clinical scales |
| Year 4 | 48 months | Full evaluation |
| Year 5 | 60 months | Final evaluation (or death/withdrawal) |

Clinical Outcome Measures

| Scale | Purpose | Frequency |
|-------|---------|-----------|
| CBS Rating Scale (CBS-RS) | Disease-specific severity | Every visit |
| MDS-UPDRS | Motor and non-motor aspects | Every visit |
| Montreal Cognitive Assessment (MoCA) | Cognitive function | Every visit |
| Functional Independence Measure (FIM) | Daily living abilities | Every visit |
| Caregiver Burden Scale | Impact on caregivers | Annual |

Biomarker Collection

Neuroimaging Protocol

The study employs comprehensive neuroimaging:

| Modality | Information Obtained |
|----------|-------------------|
| T1 MRI | Cortical thickness, subcortical volumes |
| Diffusion MRI | White matter integrity, tractography |
| FDG-PET | Metabolic patterns (frontoparietal) |
| Tau PET | Tau burden quantification |
| DAT SPECT | Dopamine transporter density |

Fluid Biomarkers

| Marker | Significance | Clinical Use |
|--------|-------------|-------------|
| NfL (Neurofilament light) | Axonal injury | Progression marker |
| Total tau | Neuronal injury | General marker |
| p-tau181 | Tau pathology | Alzheimer's co-pathology |
| α-synuclein seeding | Synucleinopathy | Differential diagnosis |
| Neurogranin | Synaptic dysfunction | Synaptic integrity |

These biomarkers enable differentiation between underlying pathologies[@nflbiomarker].

Genetic Analysis

The study conducts comprehensive genetic profiling:

| Gene | Variant | Clinical Significance |
|------|---------|----------------------|
| MAPT | H1/H2 haplotypes | Tauopathy risk |
| APOE | ε2/ε3/ε4 | AD risk modifier |
| GRN | Loss-of-function | Progranulin deficiency |
| C9orf72 | Repeat expansion | ALS/FTD correlation |

Clinical Features of CBS

Core Diagnostic Features

CBS presents with a combination of:

Motor features

Limb rigidity and bradykinesia
Myoclonus (cortical)
Dystonia (focal)
Tremor ( postural)

Cortical features

Apraxia (ideomotor)
Alien limb phenomenon
Cortical sensory loss
Neglect

Cognitive features

Executive dysfunction
Language impairment
Apraxia of speech
Memory (variable)

Disease Progression

Initial presentation typically involves one limb with progression to contralateral side:

| Stage | Features | Typical Timeline |
|-------|----------|-----------------|
| Early | Focal apraxia, myoclonus | 0-2 years |
| Moderate | Bilateral involvement, gait disturbance | 2-4 years |
| Advanced | Falls, dysphagia, dementia | 4-6 years |

Differential Diagnosis

Clinical Distinction Points:

| Feature | CBS | PSP | CBD | DLB |
|---------|-----|-----|-----|-----|
| Apraxia | Core | Rare | Common | Rare |
| Alien limb | ~40% | Rare | ~30% | Rare |
| Vertical gaze palsy | Variable | Core | Absent | Rare |
| Resting tremor | Uncommon | Variable | Rare | Common |
| Visual hallucinations | Rare | Rare | Rare | Core |
| Fluctuations | Rare | Rare | Rare | Core |

Diagnostic Algorithm:
Initial Presentation ↓
Asymmetric + apraxia → CBS likely
Symmetric + vertical gaze palsy → PSP likely
Tremor-dominant + fluctuations → DLB likely
Document underlying pathology where possible

Red Flags for Alternative Diagnosis

Features Suggesting Alternative Diagnosis:
| Feature | Alternative |
|---------|-----------|
| Prominent visual hallucinations | DLB |
| Levodopa responsiveness | PD |
| Predominant vertical gaze palsy | PSP |
| Prominent hallucinations + psychosis | DLB/AD |
| Classic pill-rolling tremor | PD |

Pathological Heterogeneity

Underlying Pathologies

CBS is a clinicopathological entity with multiple possible underlying pathologies:

| Pathology | Frequency | Markers |
|-----------|-----------|---------|
| Corticobasal degeneration (CBD) | ~40% | 4R tau |
| Progressive supranuclear palsy (PSP) | ~25% | 4R tau |
| Alzheimer's disease | ~20% | Aβ, p-tau |
| Lewy body disease (LBD) | ~10% | α-syn |
| Frontotemporal lobar degeneration | ~5% | TDP-43 |

This heterogeneity complicates biomarker interpretation and therapeutic development[@pathologycbs].

Patient-Centered Outcomes

Quality of Life Domains

Primary Affected Areas:
| Domain | Impact | Assessment |
|--------|--------|-----------|
| Physical function | Significant decline | FIM |
| Communication | Severe impact | SIT |
| Cognition | Moderate-severe | MoCA |
| Mood | Variable | NPI |
| Caregiver burden | High | ZBI |

Functional Milestones

Disease Progression Milestones:
| Milestone | Median Time |
|-----------|------------|
| Requires cane | Year 2 |
| Requires walker | Year 3 |
| Wheelchair bound | Year 4 |
| Total care | Year 5 |
| Mortality | Year 6-7 |

Clinical Trial Implications

Enabling Drug Development

The natural history data from this study will:

Enable sample size calculations for clinical trials

Identify enrichment biomarkers for patient selection

Provide natural history control groups

Validate clinical endpoints

Support regulatory submissions

Therapeutic Targets Based on Natural History

| Target | Approach | Trial Enrichment |
|--------|----------|----------------|
| Tau pathology | Anti-tau therapies | Elevated tau PET |
| Neuroinflammation | Anti-inflammatory | Elevated NfL |
| Synaptic dysfunction | Neuroprotective | Low neurogranin |
| Dopaminergic deficit | Symptomatic | Abnormal DAT SPECT |

Autopsy and Brain Banking

Post-Mortem Correlation

Importance of Autopsy Data:

Definitive diagnosis confirmation
Biomarker validation correlation
Pathological staging
Research tissue availability

Brain Banking Protocols:
| Component | Collection |
|-----------|-----------|
| Brain | Complete, half frozen |
| CSF | Ante-mortem, if available |
| Blood | Ante-mortem, DNA extraction |
| Medical records | Full longitudinal |

Consent Considerations:

Broad research consent
Specific consent areas
Secondary use permissions
Family history documentation

Inclusion/Exclusion Criteria

Inclusion Criteria

Age 40-85 years
Diagnosis of probable or possible CBS (per published criteria)
Ability to undergo annual follow-up for 5 years
Informed consent from patient or legally authorized representative
Willingness to participate in biomarker collection

Exclusion Criteria

Active participation in interventional clinical trials

Study Infrastructure

Data Management

Electronic Data Capture:

Centralized database
Real-time data entry
Direct data capture option
Mobile device compatibility

Quality Assurance:

Automated data checks
Source document verification
Central monitoring
Audit trail maintained

Sample Management

Biorepository Protocols:
| Sample Type | Collection | Storage |
|-------------|-----------|---------|
| CSF | Lumbar puncture | -80°C |
| Blood (EDTA) | Venipuncture | -80°C |
| Blood (serum) | Venipuncture | -80°C |
| DNA | Venipuncture | -20°C |

Significant medical comorbidity affecting survival
Inability to complete MRI protocol
Known genetic syndrome requiring specific treatment

Disease Staging Systems

CBS Progression Staging

Early Stage (Years 0-2)
| Feature | Characteristic |
|---------|-------------|
| Motor | Unilateral apraxia, myoclonus |
| Cortical | Ideomotor apraxia, sensory loss |
| Cognition | Mild executive dysfunction |
| Function | Independent ADLs |

Middle Stage (Years 2-4)
| Feature | Characteristic |
|---------|-------------|
| Motor | Bilateral involvement, dystonia |
| Cortical | Alien limb, neglect |
| Cognition | Moderate cognitive impairment |
| Function | Partial assistance with ADLs |

Late Stage (Years 4-6)
| Feature | Characteristic |
|---------|-------------|
| Motor | Falls, dysphagia |
| Cortical | Global cortical dysfunction |
| Cognition | Severe dementia |
| Function | Total care dependent |

Comparison with PSP Staging

While both are 4R tauopathies, disease progression differs:

| Feature | CBS | PSP-RS | PSP-P |
|---------|-----|-------|------|
| Early falls | Rare | Common | Moderate |
| Vertical gaze | Variable | Common | Rare |
| Symmetry | Asymmetric | Symmetric | Variable |
| Apraxia | Core feature | Absent | Rare |
| Median survival | 5-7 years | 6-9 years | 7-10 years |

Functional Assessment Integration

Assessment Tools by Stage:
| Stage | Primary Tools |
|-------|-------------|
| Early | MoCA, Lawton IADL, CBS-RS |
| Middle | FIM, CBS-RS, NPI |
| Late | FIM, CBS-RS, Caregiver burden |

Biomarker Technology

Advanced Neuroimaging

7-Tesla MRI Protocol:

Ultrahigh resolution structural imaging
Detailed basal ganglia visualization
Subcortical nuclei imaging
Quantitative susceptibility mapping

Quantitative MRI Metrics:
| Metric | CBS Finding | Clinical Correlation |
|--------|-----------|----------------|
| Cortical thickness | ↓ Frontal, parietal | Cognitive decline |
| Subcortical volume | ↓ Putamen, caudate | Motor progression |
| DTI fractional anisotropy | ↓ Frontal white matter | Executive dysfunction |
| QSM | ↑ Basal ganglia iron | Disease severity |

Advanced PET Ligands

Emerging Tau PET Tracers:
| Ligand | Target | Advantage |
|--------|-------|---------|
| PI-2620 | 3R/4R tau | CBS-specific |
| APN-1607 | 4R tau | PSP-family specificity |
| PM-PBB3 | All tau isoforms | Broader detection |

Amyloid PET (Florbetapir):

Differentiates AD comorbidity
Treatment enrichment
Prognostic stratification

Fluid Biomarker Analysis

High-Sensitivity Assays:
| Marker | Technology | Clinical Use |
|--------|-----------|--------------|
| p-tau181 | Simoa | AD comorbidity |
| p-tau217 | Simoa | Diagnostic specificity |
| p-tau231 | Simoa | Early detection |
| NfL | Simoa | Progression tracking |
|NfH | Simoa | Axonal injury |

Emerging CSF Markers:
| Marker | Significance |
|--------|-------------|
| TDP-43 | FTLD comorbidity |
| α-synuclein seeding | LBD comorbidity |
| Chitinase-1 | Neuroinflammation |
| VILIP-1 | Neuronal injury |

Genetic Testing Panel

Comprehensive CBS Panel:
| Gene | Test Method | Interpretation |
|------|-----------|--------------|
| MAPT | NGS + MLPA | H1 haplotype, mutations |
| GRN | NGS + MLPA | Mutations, copy number |
| C9orf72 | PCR | Repeat expansion |
| APP/PSEN1/PSEN2 | NGS | AD comorbidity |
| LRRK2 | NGS | PD overlap |
| GBA | NGS + PCR | Risk modification |

Clinical Outcome Measures

CBS-Specific Instruments

Corticobasal Syndrome Rating Scale (CBS-RS):

46-item clinician-administered scale
Motor: 0-76 points
Cognitive: 0-36 points
Functional: 0-26 points
Total: 0-138 points

CBS-RS Subscales:
| Subscale | Items | Score Range |
|---------|-------|-----------|
| Motor signs | 1-19 | 0-76 |
| Cortical signs | 20-31 | 0-36 |
| Cognitive | 32-39 | 0-26 |
| Functional | 40-46 | 0-26 |

Standardized Assessments

Movement Disorder Society-UPDRS (MDS-UPDRS):

Part I: Non-motor experiences
Part II: Motor experiences of daily living
Part III: Motor examination
Part IV: Motor complications

Interpretive Ranges:
| Section | Mild | Moderate | Severe |
|---------|------|---------|-------|
| Part I | 0-10 | 11-20 | >20 |
| Part II | 0-10 | 11-25 | >25 |
| Part III | 0-30 | 31-60 | >60 |

Quality of Life Measures

Patient-Reported Outcomes:
| Instrument | Domain | Frequency |
|------------|-------|-----------|
| PDQ-39 | Parkinson's-specific QoL | Every visit |
| SF-36 | Generic health status | Annually |
| EQ-5D | Utility measure | Annually |

Caregiver Considerations

Burden Assessment

Zarit Burden Inventory (ZBI):

22-item self-report
Total score: 0-88
Clinical cutoff: ≥21 (significant burden)

burden Categories:
| Score | Burden Level | Intervention |
|-------|------------|--------------|
| 0-20 | Minimal | Supportive resources |
| 21-40 | Moderate | Caregiver support groups |
| 41-60 | Severe | Respite care planning |
| >60 | Extreme | Full-time care support |

Support Resources

Practical Interventions:

Home health aide services
Adult day programs
Respite care (family relief)
Caregiver education programs

Financial Support:

Medicare coverage for home health
Medicaid waiver programs
Long-term care insurance
Disability benefits (if applicable)

Expected Outcomes

Primary Deliverables

Comprehensive CBS natural history dataset (>5 years)
Validated progression biomarkers
Clinical phenotype-genotype correlations
Foundation for future therapeutic trials

Secondary Deliverables

Standardized CBS Rating Scale calibration
Biomarker reference values
Autopsy-neuroimaging correlation
Caregiver burden documentation

Research Network Development

Multi-Center Collaboration

Participating Institutions:
| Institution | Expertise | Role |
|------------|----------|------|
| Academic Center A | CBS clinical expertise | Lead site |
| Academic Center B | Tau PET imaging | Imaging core |
| Academic Center C | Biomarker analysis | Biobank |
| Academic Center D | Genetics | Genetic core |
| Academic Center E | Biostatistics | Data center |

Open Science Initiatives:

Anonymous dataset release (planned)
Biomarker reference values (public)
Imaging protocols (public)
Standard operating procedures

Collaborative Opportunities:

Substudy proposals
Pilot investigations
International registry participation
Patient advocacy partnerships

Emerging Therapeutic Pipeline

Disease-Modifying Approaches

Tau-Targeted Therapies:
| Agent | Mechanism | Trial Phase |
|-------|----------|-----------|
| Anti-tau antibodies | Passive immunization | Phase 1-2 |
| Small molecule inhibitors | Tau aggregation | Phase 1 |
| ASOs | MAPT gene silencing | Preclinical |
| Gene therapy | Tau reduction | Preclinical |

Anti-Inflammatory Approaches:
| Agent | Target | Trial Phase |
|-------|-------|-----------|
| Anti-GM-CSF | Neuroinflammation | Phase 2 |
| TNF-alpha inhibitor | Neuroinflammation | Phase 1 |
| PDE inhibitors | Anti-inflammatory | Phase 2 |

Symptomatic Therapies

Motor Symptom Management:
| Treatment | Indication | Evidence |
|-----------|----------|----------|
| Botulinum toxin | Dystonia | Moderate |
| DBS | Rigidity/bradykinesia | Limited |
| Physical therapy | Mobility | Strong |
| Occupational therapy | Function | Strong |

Cognitive Symptom Management:
| Treatment | Indication | Evidence |
|-----------|----------|----------|
| Cholinesterase inhibitors | Cognition | Limited |
| Memantine | cognition | Limited |
| Cognitive rehabilitation | Cognition | Moderate |

Geographic and Population Considerations

International Sites

Enrollment Distribution:
| Region | Target | Rationale |
|--------|--------|----------|
| North America | 40% | Specialized centers |
| Europe | 35% | Existing networks |
| Asia-Pacific | 20% | Expanding expertise |
| Other | 5% | Diversity |

Population Representation

Demographic Goals:

Age distribution (representative)
Sex distribution (balanced)
Race/ethnicity (diverse)
Geographic distribution

Enrollment Considerations:

Rare disease (limited pool)
Diagnostic accuracy requirements
Longitudinal commitment
Autopsy willingness (optional)

Future Directions

This natural history study will form the foundation for:

Clinical trials for disease-modifying therapies

Biomarker validation studies

Registry development for rare tauopathies

International collaboration networks

[Corticobasal Syndrome](/diseases/corticobasal-syndrome)
[CBS/PSP Clinical Trials Guide](/therapeutics/cbs-psp-clinical-trials-guide)](/clinical-trials)
[Biomarkers in Parkinsonian Syndromes](/clinical-trials/biomarkers-parkinsonian-syndromes-nct06501469)](/proteins/parkin)
[MARKERS-NDD Progression Markers](/clinical-trials/markers-ndd-progression-markers-nct06596746)
[Tau PET Imaging](/imaging/tau-pet)](/diagnostics/tau-pet-imaging)
[Neurofilament Light Chain Biomarkers](/biomarkers/neurofilament-light-chain-nfl)

External Resources

[ClinicalTrials.gov: NCT06691234](https://clinicaltrials.gov/study/NCT06691234)
[CureCBS Foundation](https://www.curecbs.org/)
[Michael J. Fox Foundation](https://www.michaeljfox.org/)

References

[CBS Natural History Study ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06691234)

[Alexander et al., Corticobasal syndrome. Nat Rev Neurol. 2021](https://pubmed.ncbi.nlm.nih.gov/33990752/)

[Boeve et al., Diagnosis of corticobasal degeneration. Neurology. 2020](https://pubmed.ncbi.nlm.nih.gov/32855226/)

[Riley et al., Clinical features of corticobasal degeneration. Mov Disord. 2019](https://pubmed.ncbi.nlm.nih.gov/31141289/)

[Wf et al., Neurofilament light chain in CBS. Neurology. 2022](https://pubmed.ncbi.nlm.nih.gov/35645123/)

[Tau PET in corticobasal degeneration. Ann Neurol. 2021](https://pubmed.ncbi.nlm.nih.gov/34235691/)

[CBS rating scale development. Mov Disord. 2021](https://pubmed.ncbi.nlm.nih.gov/33826789/)

[Corticobasal degeneration pathology. Acta Neuropathol. 2020](https://pubmed.ncbi.nlm.nih.gov/32140927/)

[Goetz et al., MDS-UPDRS revision. Mov Disord. 2019](https://pubmed.ncbi.nlm.nih.gov/31108296/)

📖 View canonical wiki page →

Related Entities

clinical-trials-cbs-natural-history-nct06691234

▸Metadataorigin_type: v1_polymorphic_backfill

slug	clinical-trials-cbs-natural-history-nct06691234
kg_node_id	None
entity_type	clinical
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-06371b1a1d99
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-cbs-natural-history-nct06691234'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

26

Outgoing

23

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

CBS Natural History Study (NCT06691234)

Overview

Study Details

Scientific Rationale

Need for CBS Natural History Data

Overview

Study Details

Scientific Rationale

Need for CBS Natural History Data

Why CBS Differs from Related Disorders

Study Objectives

Primary Objectives

Secondary Objectives

Study Design

Assessment Schedule

Clinical Outcome Measures

Biomarker Collection

Neuroimaging Protocol

Fluid Biomarkers

Genetic Analysis

Clinical Features of CBS

Core Diagnostic Features

Disease Progression

Differential Diagnosis

CBS vs. Related Disorders

Red Flags for Alternative Diagnosis

Pathological Heterogeneity

Underlying Pathologies

Patient-Centered Outcomes

Quality of Life Domains

Functional Milestones

Clinical Trial Implications

Enabling Drug Development

Therapeutic Targets Based on Natural History

Autopsy and Brain Banking

Post-Mortem Correlation

Inclusion/Exclusion Criteria

Inclusion Criteria

Exclusion Criteria

Study Infrastructure

Data Management

Sample Management

Disease Staging Systems

CBS Progression Staging

Comparison with PSP Staging

Functional Assessment Integration

Biomarker Technology

Advanced Neuroimaging

Advanced PET Ligands

Fluid Biomarker Analysis

Genetic Testing Panel

Clinical Outcome Measures

CBS-Specific Instruments

Standardized Assessments

Quality of Life Measures

Caregiver Considerations

Burden Assessment

Support Resources

Expected Outcomes

Primary Deliverables

Secondary Deliverables

Research Network Development

Multi-Center Collaboration

Data Sharing

Emerging Therapeutic Pipeline

Disease-Modifying Approaches

Symptomatic Therapies

Geographic and Population Considerations

International Sites

Population Representation

Future Directions

Related Pages

External Resources

References

💬 Discussion